dbo:abstract |
Blarcamesine (development code ANAVEX2-73) is an experimental drug developed by Anavex Life Sciences. It is in phase IIb/phase III trials for Alzheimer's disease and Rett syndrome, phase IIa trials for Parkinson's disease, phase I trials for epilepsy, and in preclinical trials for amyotrophic lateral sclerosis and stroke. Blarcamesine acts as a muscarinic receptor and a moderate sigma1 receptor agonist. In trials for Alzheimer's disease, Anavex Life Sciences reported that in patients with a fully functional SIGMAR1 gene, which encodes the sigma-1 receptor targeted by blarcamesine, the drug improved cognition as measured by the mini-mental state examination by 14% after 70 weeks of treatment. Competence in activities of daily living was improved by 8% in the same subgroup of patients. Additionally, in trials for Parkinson's disease, episodic memory was significantly improved after 14 weeks of treatment. (en) |
dbo:casNumber |
195615-83-9 |
dbo:chEMBL |
4297224 |
dbo:drugbank |
DB05592 |
dbo:fdaUniiCode |
9T210MMZ3F |
dbo:inn |
blarcamesine |
dbo:kegg |
D11383 |
dbo:pubchem |
9882189 |
dbo:thumbnail |
wiki-commons:Special:FilePath/ANAVEX2-73.svg?width=300 |
dbo:wikiPageID |
50631740 (xsd:integer) |
dbo:wikiPageLength |
9399 (xsd:nonNegativeInteger) |
dbo:wikiPageRevisionID |
1080257846 (xsd:integer) |
dbo:wikiPageWikiLink |
dbr:Bcl-2 dbr:Bcl-2-associated_X_protein dbr:Endoplasmic_reticulum dbr:Epilepsy dbr:Motion_sickness dbr:Short-term_memory dbr:Cytochrome_c dbr:Cytosol dbc:Dimethylamino_compounds dbc:Prodrugs dbr:Competitive_inhibition dbr:Memantine dbr:Mitochondria dbr:Phase_III_trial dbr:Phase_II_trial dbr:Phase_I_trial dbr:Apoptosis dbr:Activities_of_daily_living dbr:Lipid_peroxidation dbr:Long-term_memory dbr:Acetylcholinesterase dbr:Agonist dbr:Amyloid_precursor_protein dbr:Amyotrophic_lateral_sclerosis dbc:Muscarinic_antagonists dbc:Sigma_agonists dbr:Alzheimer's_disease dbr:Parkinson's_disease dbr:Rett_syndrome dbr:Hyperphosphorylation dbr:Donepezil dbr:Hyoscine_hydrobromide dbr:NMDA_receptor dbr:Oxidative_stress dbr:Mini-mental_state_examination dbr:Amyloid-beta dbr:Amyloid-beta_peptide dbr:SIGMAR1 dbr:GSK-3B dbr:Tau_plaque dbr:Sigma1 dbr:Sigma1_receptor dbr:Muscarinic_receptor dbr:Nuclear_factor_kB dbr:Pro-drug dbr:Preclinical_trial dbr:Β-secretase dbr:AF267B dbr:ANAVEX19-144 dbr:ANAVEX_1-41 dbr:Anti-apoptoic dbr:Aβ25-35 |
dbp:c |
19 (xsd:integer) |
dbp:casNumber |
195615 (xsd:integer) |
dbp:chembl |
4297224 (xsd:integer) |
dbp:chemspiderid |
8057864 (xsd:integer) |
dbp:drugName |
Blarcamesine (en) |
dbp:drugbank |
DB05592 (en) |
dbp:h |
23 (xsd:integer) |
dbp:inn |
blarcamesine (en) |
dbp:iupacName |
1 (xsd:integer) |
dbp:kegg |
D11383 (en) |
dbp:legalStatus |
Investigational (en) |
dbp:n |
1 (xsd:integer) |
dbp:o |
1 (xsd:integer) |
dbp:pubchem |
9882189 (xsd:integer) |
dbp:smiles |
O3CCCC3 (en) |
dbp:stdinchi |
1 (xsd:integer) |
dbp:stdinchikey |
BOTHKNZTGGXFEQ-UHFFFAOYSA-N (en) |
dbp:synonyms |
ANAVEX2-73 (en) |
dbp:unii |
9 (xsd:integer) |
dbp:wikiPageUsesTemplate |
dbt:Acetylcholine_receptor_modulators dbt:Clarify dbt:Infobox_drug dbt:Multiple_issues dbt:Primary_sources dbt:Reflist dbt:Short_description dbt:Technical dbt:Sigma_receptor_modulators |
dcterms:subject |
dbc:Dimethylamino_compounds dbc:Prodrugs dbc:Muscarinic_antagonists dbc:Sigma_agonists |
rdf:type |
owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 dbo:Drug |
rdfs:comment |
Blarcamesine (development code ANAVEX2-73) is an experimental drug developed by Anavex Life Sciences. It is in phase IIb/phase III trials for Alzheimer's disease and Rett syndrome, phase IIa trials for Parkinson's disease, phase I trials for epilepsy, and in preclinical trials for amyotrophic lateral sclerosis and stroke. Blarcamesine acts as a muscarinic receptor and a moderate sigma1 receptor agonist. (en) |
rdfs:label |
Blarcamesine (en) |
owl:sameAs |
wikidata:Blarcamesine https://global.dbpedia.org/id/2N8fU |
prov:wasDerivedFrom |
wikipedia-en:Blarcamesine?oldid=1080257846&ns=0 |
foaf:depiction |
wiki-commons:Special:FilePath/ANAVEX2-73.svg |
foaf:isPrimaryTopicOf |
wikipedia-en:Blarcamesine |
foaf:name |
Blarcamesine (en) |
is dbo:wikiPageRedirects of |
dbr:ANAVEX2-73 dbr:Anavex_2-73 dbr:ANAVEX-2-73 |
is dbo:wikiPageWikiLink of |
dbr:C19H23NO dbr:ANAVEX2-73 dbr:Anavex_2-73 dbr:ANAVEX-2-73 |
is foaf:primaryTopic of |
wikipedia-en:Blarcamesine |